All that appears to be required is one test implemented to run on Abbott's automated analyzer that will detect the presence of the RECAF receptors on the surface of malignant cells found in blood samples.
The announcement of the Abbott deal first milestone has to be very close. kag
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.